Home › Compare › THTX vs O

THTX vs O: Dividend Comparison 2026

THTX yields 59.00% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THTX wins by $586.0K in total portfolio value
10 years
THTX
THTX
● Live price
59.00%
Share price
$3.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$620.2K
Annual income
$143,088.77
Full THTX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — THTX vs O

📍 THTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHTXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THTX + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
THTX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THTX
Annual income on $10K today (after 15% tax)
$5,014.75/yr
After 10yr DRIP, annual income (after tax)
$121,625.45/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, THTX beats the other by $117,288.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THTX + O for your $10,000?

THTX: 50%O: 50%
100% O50/50100% THTX
Portfolio after 10yr
$327.2K
Annual income
$74,095.75/yr
Blended yield
22.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

THTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-8.8
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THTX buys
0
O buys
0
No recent congressional trades found for THTX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHTXO
Forward yield59.00% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$620.2K ✓$34.2K
Annual income after 10y$143,088.77 ✓$5,102.74
Total dividends collected$512.6K ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: THTX vs O ($10,000, DRIP)

YearTHTX PortfolioTHTX Income/yrO PortfolioO Income/yrGap
1← crossover$16,600$5,899.71$10,818$608.16+$5.8K → THTX
2$26,914$9,152.65$11,787$741.68+$15.1K → THTX
3$42,667$13,869.04$12,946$911.00+$29.7K → THTX
4$66,202$20,548.25$14,345$1,127.94+$51.9K → THTX
5$100,633$29,796.73$16,056$1,409.05+$84.6K → THTX
6$150,008$42,330.45$18,171$1,777.83+$131.8K → THTX
7$219,480$58,971.49$20,820$2,268.21+$198.7K → THTX
8$315,482$80,637.85$24,188$2,929.90+$291.3K → THTX
9$445,892$108,326.32$28,533$3,837.11+$417.4K → THTX
10$620,193$143,088.77$34,235$5,102.74+$586.0K → THTX

THTX vs O: Complete Analysis 2026

THTX — Stock

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Full THTX Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this THTX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THTX vs SCHDTHTX vs JEPITHTX vs KOTHTX vs MAINTHTX vs STAGTHTX vs ADCTHTX vs NNNTHTX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.